If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 251 - 260 of 299
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Patients With Endocrine-Resistant Hormone
Objective
A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Protocol No
HOFFMAN-LAROCHE-CO46274
Categories
Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin with Split-Dose CHP Chemotherapy for Elderly Patients with Diffuse Large B-Cell Lymphoma
Objective
MCW ELDERLY DLBCL STUDY
Protocol No
IIT-SHAH-ELDERLY-DLBCL
Categories
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer
Objective
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Protocol No
OLEMA-OP-1250-302-OPERA
Categories
A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects with Severe Refractory Autoimmune Diseases
Objective
US Zamto-cel Autoimmune Diseases
Protocol No
RHEU-MILTENYI-M-2024-423
Categories
A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants with Advanced Solid Tumors
Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Single, Site, Pragmatic Pilot Study
Objective
Impact of Glucagon-like Peptide on Disease Outcomes
Protocol No
RHEU-IIT-SINGLA-GLP-1
Categories
The Intersection of GLP-1, Gut Microbiota, and Brain Connectivity in Prodromal Alzheimer's Disease
Objective
GLP-1, Gut Microbiota, and Brain Connectivity in AD
Protocol No
NEURO-NIH-MICROBIOME-GLP-1-AD
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Phnegative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly-Diagnosed Older Adults or Adults With Relapsed or Refractory Disease and Feasibility Study of Ponatinib Wi
Objective
A Phase 2 Study of Inotuzamab Ozogamicin in Patients with ALL in Newly Diagnosed Adults
Protocol No
ALLIANCE-A041703
Categories
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Objective
Trial of Zanubrutinib in older patients with mantle cell lymphoma
Protocol No
ALLIANCE-A052101
Categories
An Open-Label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Objective
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Protocol No
CORCEPT-CORT125134-557-BELLA
Categories